Alnylam Pharmaceuticals Inc. (ALNY)
NASDAQ: ALNYHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 224.41 0.00%
ALNY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $30.03B
- P/E (TTM)
- 37.84
- Forward P/E
- 17.99
- EPS (TTM)
- $5.93
- Dividend yield
- None
- 52-week range
- 197.81 – 495.55
- Day range
- 222.46 – 230.42
- Volume / Avg
- 1.06M / 1.84M
- Beta
- —
- Shares outstanding
- 133.81M
- Next earnings
- Oct 29, 2026
52-week range
ALNY stock today
Shares of Alnylam Pharmaceuticals (ALNY) finished higher on Oct 7 at $224.41, a gain of 0.21% or $0.47 per share, versus the S&P 500's 0.22% decline. At this level, ALNY sits near the bottom of its 52-week range of $197.81 to $495.55: 54.7% below the high, set on Oct 20, 2025 and 13.4% above the low. ALNY is down 43.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 50.7%.
At 37.8x trailing earnings, Alnylam Pharmaceuticals trades above the peer-group median of 29.9x. Its forward P/E of 18.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Alnylam Pharmaceuticals's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Alnylam Pharmaceuticals
Company profileAlnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Yvonne L. Greenstreet M.B.A., M.D.
- Headquarters
- Cambridge, MA
- Employees
- 2,500
- IPO year
- 2004
- Website
- alnylam.com
Financial highlights
Full financialsIn fiscal 2025, Alnylam Pharmaceuticals generated $3.71 billion in revenue, up 65.2% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $313.7 million, for a net margin of 8.4% versus a median of -101.0% in the prior 5 years. Gross margin was 81.8% (down from 86.4%) and operating margin 13.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.29M |
| Growth | +65.19% | +22.97% | +76.23% | +22.88% | +71.31% |
| Net income | $313.75M | $-278.16M | $-440.24M | $-1.13B | $-852.82M |
| EPS (diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Analyst forecast
ForecastConsensus (29 analysts)
buy
Avg. price target
$371.12+65.38%
- Strong buy 6
- Buy 16
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $1.68
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $1.21 vs —
ALNY news
All ALNY newsAlnylam Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs ALNY |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs ALNY |
| BNTXBioNTech SE ADR | 95.25 | -0.50% | $23.93B | vs ALNY |
| INCYIncyte Corp. | 113.44 | +0.63% | $22.99B | vs ALNY |
| GMABGenmab A/S ADS | 36.65 | -3.04% | $22.54B | vs ALNY |
| INSMInsmed Incorporated | 101.74 | -3.32% | $22.22B | vs ALNY |
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs ALNY |
| RVMDRevolution Medicines Inc. | 200.87 | +0.50% | $43.05B | vs ALNY |
Indexes, lists and sector
Index membership
Appears in lists
Alnylam Pharmaceuticals stock FAQ
What is Alnylam Pharmaceuticals's stock price today?
ALNY last traded at $224.41 as of Oct 7, 4:00 PM EDT, up 0.21% on the day. Prices are delayed at least 15 minutes.
When is Alnylam Pharmaceuticals's next earnings date?
Alnylam Pharmaceuticals is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $1.68.
What is ALNY's P/E ratio?
ALNY trades at a trailing P/E ratio of 37.84 and a forward P/E of 17.99, compared with a median of 29.9 for its closest peers.
Is Alnylam Pharmaceuticals in the S&P 500?
No. Alnylam Pharmaceuticals is not currently a member of the S&P 500; it is included in the NDX.
Who is Alnylam Pharmaceuticals's CEO?
Dr. Yvonne L. Greenstreet M.B.A., M.D. is the chief executive officer of Alnylam Pharmaceuticals Inc., which has about 2,500 employees.
What is the ALNY 52-week high?
The 52-week high for ALNY is $495.55 and the 52-week low is $197.81. The stock is currently 54.7% below its high.